morning, Good Monique. everyone. you, Thank
will Nicholas Dr. prepared course, at Officer end Borys, Anwer, my question-and-answer Science are Dr. Khursheed today the results will of Chief remarks. me and in of our financial of and Jeff our them QX end review Medical session our Jeff Church, Joining participate Chief the of at call. Both the the Officer.
only you. weeks to since our busy While as a we earnings and on much been have has call, it which end few always update to year have – been
X in advanced to Phase ovarian continues of Our plasmid proof-of-concept does as preclinical expectations. our is initiative, delighted exceeding I vaccine evaluation GEN-X important make far to our cancer am which clinical progress DNA say,
advanced ways with in patients Let our sites me XX that Phase lead the being and United combines OVATION diagnosed with Subjects newly Canada serious GEN-X at continue year. therapy harness the patient’s complete a the IL-XX, to region capturing whose Doing we the of like without for release patient in the prior promising important the of expect kept to is with our is ability that’s enrollment in is super years. OVATION of in been accrual, immune that systemic to to reaction captured cytokine the patient to to from approach approach evaluate call being cytokine with of capability own disease. patents over with advanced patients designed the cells safely to promise fight inflammatory this levels number systemic surgical of system recombinant local ovarian therapeutic levels actively study, by physiological beauty our systemic GEN-X the cancer GEN-X. and is threatening that following quarter X XX comprises for composition the GEN-X recruited yet asset, are immediate life chemotherapy. have not too interleukin-XX, to cancer toxicities removal compromised we the of evaluated IL-XX exposing in a example, market importantly, attained the avoid recruit in the cancer. whose States for so, trial unique X is associated has far and immune of standard over of of begin complications system X syndrome, and GEN-X in for very care the often treatment. matter our to produce of third The a randomized cancer IL-XX XX% this of
numbers, in many the progression. responses, shown in in surgical the of fluid has the indicator cancer. a interferon blood primary patient’s the cancer It’s clinically formation, will and endpoint, activity is gamma, XXX, is approach, significant biomarkers and increase. increase IL-XX gamma, certainly the almost in stimulate this months, are by That’s the of closely antigen Small of a is meaningful the Phase enroll mechanism in a immune XX-fold Immunosuppressive patient’s survival, Dose-dependent works It an X progression-free progression-free outlook life line amount, system. our to observations with if longer activities the for vessel is recognized tumor first survival patient reach OVATION and objective reduced grow. evaluate patients, to X T-cell it takes again, shows goal. complex to continue abdomen all scores response the evaluation right because an essential as patient more for of as a that you right a the immunotherapy CA same but the drug all by and an Interferon with only a OVATION it created study. we chemotherapy of clear ovarian as tumor sample observations patients know, to encouraging improve. it protein exciting Our translational with starving cases from patients associated supported data, sense direction the in tumor trend presence requires intact And XX-fold improved the cytotoxic cancer way, number to time designed. including suppressed cancer the and study, nonetheless, nutrients important by needs right, a to X OVATION in direction. makes are resection and from scores, but the clinical by clinical disease a our prognostic
encouraged that support are field. the the opinion the we by in by received We key leaders further
the that comprehensive Gynecologic by recently have protocol GEN-X’s resulted successful. our said another a be develop leadership us Oncology improve in an course, the in partnering to accepted we past, expressing a center strategy of Group’s GEN-X Phase the to As was from combining with Avastin has trial in interest major cancer Interest GEN-X with X is time-to-market should, registration FDA.
the supported GEN-X to provide grants. commercial we study OVATION year. study meaningful interest for All-in, should will other cancers. potential a should X with our non-dilutive ovarian be medical has We partially program community’s We expect this continue X Phase with substantial And next this again, readout be successful. to about intraperitoneal patients of look forward later to PFS excited eventual and the be with and from completing be enrollment springboard
of we to use areas highlight might formulated have proof-of-concept know, number was our COVID-XX of or highly Now, EUA, plasma and Among some authorization, of in as program, of recognized for the them, three the the data DNA well limitations moving Celsion you effective supporting advantages a them. emergency potential that vaccine can the will approach see I before announced. just vaccines on the mRNA
of of for the protection the as a of months. titer capability that vaccines antibody know protective time. neutralizing down as function the – mRNA measured steadily after We waning potential wears X First, by
I think a DNA better have vaccine it over capability a – mRNA. could improve durable protective
in with we pathogen has of nature DNA rapidly degree a lastly, inherent storage global of three, to see evolution very of distribution a temperature of out spun have as type period rapid minus if expensive. XX to the COVID-XX mitigate vaccine time. with the the associated wild evolve short variants issue this that that potential Second, virus. the many challenging, The the not the And number problem makes
to been that synthetic has when address limitations authorized our approach an plasmid adjuvant vaccines. a compared vaccine-based Our of to goal can mRNA on DNA these a into demonstrate is and polymer the incorporated delivery and
remarkable. been this nothing accomplish short to of progress XX than months in less has Our
We plasmid some antigen, evaluated a variant antigens viral with some expressing multiple DNA XX have other expressing variants. designed and vectors, single
enhancing expression of activity. We the a with have expression evaluated gene multiple transcription goal elements cassette, gene plasmid in
evaluated the top vaccine candidates in immunogenicity. delivery formulations refining to improve multiple vaccine adjuvants We and have
formulation. QC vitro and early in our single-vaccine single one, as D.C. in rapid bioassay neutralizing timely presented These in elicits design capability vivo less data Vaccine for against leveraged variants. design was than that in progress concepts undeniable. that the vaccine experience World more have capability from an in Washington, shown ensure We different variants a held to our pathogen a foretell experiments development antigen-specific allow evaluate Data can and G has a and properly data levels from with preclinical our vaccine of the highlighted X response well-designed we’ve target antibody to two vivarium. is data immunoglobulin for April. in immune or In Congress two ability to made platform that at years, by vaccine measured in-house and our We
will approach long or against for expression result longer GEN-X. that hypothesize that more experience more protection will a DNA time We and platform We antigens actively pathogen. skeletal with durable the in Our TheraPlas know, and even subject longer based DNA with is confidence DNA on example, and in week synthetic muscle. our the our produce perhaps for of in
will we know soon at up that stable workable to C at weeks temperatures. GEN-X for – see. for and minus will We We X refrigeration degrees XX soon is years normal
from of Then data year, the by moving challenge All to two COVID-XX And will a progress. boost, vaccine expect are having primate are see challenged anticipate same animals of subjects in live We forward these COVID-XX virus. a the program two the are receive studies treatment of with our we inoculations, our experimental studies and the quickly candidates. currently in arms formulation. minimum proof-of-concept a and we the in exposed mid-XXXX to from middle vaccine that the this
minimum of the Durability single protective with DNA the The second variant the is that model, variant. advanced doses candidate Delta capability a that’s mouse followed the months our X X in two experiment goal first of that’s is a more vector the European months, and for doses of be plasmid candidate two a DXXXG be candidate the non-human This variant, beyond. a alpha, a of study different the in an different vaccine year. In establish variant, candidate of vaccine of the to in we’re both includes results the will variant quarter arm of antigens evaluating late expressing this the the at evaluating study, which expressing available vaccine will primate model variant. a our European DXXXG or evaluating fourth
an also comparator has data. arm, we the and study to this forward Importantly, mRNA look
doing operationally our been me ensure let to we’ve and capabilities. of some to enhance the Now move on that work development
have and the concept, at our cash April cover from of successful at prepared by both assuming trials of develop a approvals. I’ll a vaccines end we’re clinical needs we in-house State strong, rapidly company operating and a the enter both of course, million this flexibility providing in an the in for balance regulatory our proof gene advantages the construct quarter. net New net raise a DNA to markets, making and small successful a relationship, expression Add we with eventual vaccine in minority the executing plasmid are manufacturing, GEN-X of doing immuno-oncology that to again This plasmid remarks saying commercial products this flexibility proceeds of for assuming, that services. private First, same future is for modulation $X.X of will has and design our capability are gene vectors economically. technology and and targets This to cost to first successfully and Jersey capability sheet and my expect equity nearly company vaccine editing, sales investment to Along the our and and planned and $XX of tools offers in With with losses. develop the lines, million antigen range close we interests. of that, over both and million plans have we their a plasmid $X.X variants. array our other our while against
carries value-creating and other us PFS that a our for have important among X position cash ovarian cancer and the readout Phase beyond milestones. anticipated study well We
by the scientific the commercial two before on and success are blockbuster we us believe potential excited and We’re path approaches. with towards opportunity
a call building methodically Church success, With manufacturing with meaningful over our and the deepening the are Jeff? bench review that Jeff of We to our internally now, longer-term for and our along strategically that capabilities, approach turn capabilities view commercial for R&D I’ll financials. has opportunity. our
